Q2 2025 Earnings Call Transcript August 18, 2025 Nyxoah S.A. misses on earnings expectations. Reported EPS is $-0.63 EPS, ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Nyxoah gains FDA approval for its Genio system, signaling a major growth milestone. Explore revenue growth, risks, and why ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to ...

Reports Q2 revenue EUR 1.34M vs. EUR 771,000 last year. “This FDA approval represents a historic milestone for Nyxoah (NYXH) and marks the ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business UpdatesAnnounced on August 8, 2025, that the U.S.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. A webcast of the presentation will be available in the Events ...

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test. Mont-Saint-Guibert, Belgium– August 2, 2022, 8:00am CET/ 2:00am ET– Nyxoah SA, a ...